Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolai Grebenchtchikov

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Chemistry|September 23, 2003
Screening for interference in immunoassaysPaul N Span, Nicolai Grebenchtchikov, J Geurts-Moespot, et al.
Plos One|July 20, 2021
Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferroneLaura Diepeveen, Rian Roelofs, Nicolai Grebenchtchikov, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 28, 2011
TRIB3 protein denotes a good prognosis in breast cancer patients and is associated with hypoxia sensitivityMarloes Wennemers, Johan Bussink, Nicolai Grebenchtchikov, et al.
The American Journal of Pathology|January 9, 2010
Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cellsValérie Gratio, Nathalie Beaufort, Lina Seiz, et al.
The Biochemical Journal|March 27, 2010
Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosaNathalie Beaufort, Paulina Seweryn, Sophie de Bentzmann, et al.
British Journal of Haematology|June 9, 2009
High-sensitive radioimmunoassay for human serum hepcidinNicolai Grebenchtchikov, Anneke J Geurts-Moespot, Joyce J C Kroot, et al.
European Cytokine Network|November 4, 2005
Development of a sensitive ELISA for the quantification of human tumour necrosis factor-alpha using 4 polyclonal antibodiesNicolai Grebenchtchikov, Johanna van der Ven-Jongekrijg, Gerard J Pesman, et al.
Cancer Research|January 28, 2004
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancerPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Clinical Chemistry|May 29, 2004
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancerLambert C J Dorssers, Nicolai Grebenchtchikov, Arend Brinkman, et al.
Cancer|July 27, 2004
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinomaPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Chemistry|September 23, 2003
Screening for interference in immunoassaysPaul N Span, Nicolai Grebenchtchikov, J Geurts-Moespot, et al.
Plos One|July 20, 2021
Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferroneLaura Diepeveen, Rian Roelofs, Nicolai Grebenchtchikov, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 28, 2011
TRIB3 protein denotes a good prognosis in breast cancer patients and is associated with hypoxia sensitivityMarloes Wennemers, Johan Bussink, Nicolai Grebenchtchikov, et al.
The American Journal of Pathology|January 9, 2010
Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cellsValérie Gratio, Nathalie Beaufort, Lina Seiz, et al.
The Biochemical Journal|March 27, 2010
Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosaNathalie Beaufort, Paulina Seweryn, Sophie de Bentzmann, et al.
British Journal of Haematology|June 9, 2009
High-sensitive radioimmunoassay for human serum hepcidinNicolai Grebenchtchikov, Anneke J Geurts-Moespot, Joyce J C Kroot, et al.
European Cytokine Network|November 4, 2005
Development of a sensitive ELISA for the quantification of human tumour necrosis factor-alpha using 4 polyclonal antibodiesNicolai Grebenchtchikov, Johanna van der Ven-Jongekrijg, Gerard J Pesman, et al.
Cancer Research|January 28, 2004
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancerPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Clinical Chemistry|May 29, 2004
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancerLambert C J Dorssers, Nicolai Grebenchtchikov, Arend Brinkman, et al.
Cancer|July 27, 2004
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinomaPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Pageof 2